1 Session 2. Developing and Maintaining a Formulary.

Slides:



Advertisements
Similar presentations
Fundamentals of Pharmacology for Veterinary Technicians
Advertisements

Common/shared responsibilities between jobs.
Management of Drug Formulary Dimitry Gotlinsky Western University Managed Care Clerkship ProPharma Pharmaceutical Consultants, Inc. 06/16/06.
Hospital Pharmacy Workflow
Medication Management
MEDICINES SELECTION & FORMULARY MANAGEMENT
Rational Use of Injections within National Drug Policies World health organisation Essential Drugs and Medicines Policy Safe Injection Global Network Cairo.
Drug Utilization Review (DUR)
Chapter 6 Referencing Copyright © 2004 by Elsevier Inc. All rights reserved.
Hospital Pharmacy Payam Parchamazad, PharmD Staff Pharmacist
Drug Information Science
International Experience in Pharmaceutical Services for Promoting Access to Medicines: Canada, Cuba, England, Mexico International Seminar on the Challenges.
GOOD PHARMACY PRACTICE
Pharmacology Application in Athletic Training Michelle Odai, MS, LAT, ATC, CSCS Florida International University.
Omnibus Budget Reconciliation Act (OBRA-90) Goal To save money.
Drug and Therapeutics Committee Session 7A. Identifying Problems with Medicine Use: Indicator Studies.
1 Drug and Therapeutics Committee Session 10. Standard Treatment Guidelines.
TBS November 4, |1 | AMR and appropriate use of antimicrobials Nicola Magrini and Jane Robertson Policy, Access and Use Team, EMP TBS 4 November.
AND GENERIC DRUGS BRAND-NAME AND GENERIC DRUGS WHAT TO CHOOSE? Natalia VEZIKOVA, MD, PhD, Natalia VEZIKOVA, MD, PhD, MSc The Head of the Hospital Therapy.
Clinical Pharmacy Basma Y. Kentab MSc..
1 Drug and Therapeutics Committee. Objectives  Discuss the use of aggregate data including defined daily dose in analyzing the consumption of medicines.
Community pharmacy. Actions of community pharmacists in society Procurement of medicines that are suitable for human consumption Storage of medicines.
Clinical pharmacy Dr. Mohammed Al-Rekabi Lecture One First Semester.
Drug and Therapeutics Committee Session 11. Drug Use Evaluation.
Pharmacy and Therapeutics Committee
Drug Information Resources
VETERINARY DRUG USE AND PRESCRIBING CH. 5. –All drugs have 3 names Chemical name Generic (nonproprietary) name Trade (proprietary) name.
Dr. Rosaline Kinuthia Clinical pharmacist KNH. Optimize patients outcomes through the judicious, safe, efficacious, appropriate and cost effective use.
Rational Use of Drug Ali Abad hospital April 12 th, 2005.
Dr. Tahereh Safarnavadeh Clinical Pharmacist The Formulary Process In the Name of GOD.
Systematic Reviews.
State of New Hampshire Pharmacy Benefit Changes Effective November 1, 2011 Presented By: Melisa Briggs.
Clinical Pharmacy Part 2
Introduction to Pharmacology PHARM TECH. Pharmacology  Pharmacology is the science that deals with the study of therapeutic (beneficial) agents.  Knowledge.
OVERVIEW OF THE ZIMBABWE NATIONAL MEDICINES POLICY Dr C E Ndhlovu, M Med Sci, FRCP Chairperson, NMTPAC Deputy Dean, UZCHS National workshop, Jan 22-23,
ACCESS TO MEDICINES - POLICY AND ISSUES
ABSTRACT Title: Developing National Formularies Based on the WHO Model Formulary Authors: Tisocki K 3, Laing RL 1, Hogerzeil H 1, Mehta DK 2, Ryan RSM.
Social Pharmacy Lecture no. 6 Rational use of drugs Dr. Padma GM Rao
Promoting Drug and Therapeutics Committees in the Developing World
ASPECTS AFFECTING THE HOSPITAL OPERATION Financial Financial Operational Operational Administrative Administrative Clinical Clinical Safety Safety.
Determinants of Rational Use of Medicines Dr A K Sharma Prof & Head Dept of Pharmacology AFMC, Pune.
Emtenan AlHarbi,Mcs Clinical pharmacist
Development and Implementation of Good Pharmacy Practice Standards in Developing Countries Author: Frokjaer B, International Pharmaceutical Federation.
Medicaid Fee-for-Service: Prior Authorization Criteria & the Role of the DUR Board Charles Agte, Pharmacy Administrator Health Care Services June 19, 2013.
“USAPI-PHARMACY ASSOCIATION - RESPONSE TO NCD ROADMAP” Evelyn Ahhing-Faaiuaso RPH PHARMD Pihoa 51 st 1-18 nov 2011 Evelyn Ahhing-Faaiuaso RPH PHARMD Pihoa.
COMPARATIVE ANALYSIS OF SELECTED ESSENTIAL DRUG LISTS AZIZ JAFAROV/RICHARD LAING.
DRUG FORMULARY.
Consultant Advance Research Team. Outline UNDERSTANDING M&E DATA NEEDS PEOPLE, PARTNERSHIP AND PLANNING 1.Organizational structures with HIV M&E functions.
MEDICATION MANAGEMENT P&T COMMITTEE AND FORMULARY MANAGEMENT EMTENAN ALHARBI, Msc CLINICAL PHARMACIST.
Selection of essential medicines Richard Laing and Deidre Dimancesco TBS 2011 Department of Essential Medicines & Pharmaceutical Policies TBS 2008.
MONITORING THE PHARMACEUTICAL SECTOR IN A DEVELOPING COUNTRY - THE GHANA EXAMPLE Gyansa-Lutterodt M. 1,7, Andrews E 2, Arhinful D 3,7, Addo-Atuah J 4,7,
DEVELOPING NATIONAL FORMULARIES BASED ON THE WHO MODEL FORMULARY Tisocki K, Laing RL, Hogerzeil H, Mehta DK, Ryan RSM.
Drug Formulary Development & Management
Off Label Use in Managed Care Pharmacy Presentation Developed for the Academy of Managed Care Pharmacy Updated February 2015.
Technology, Information Systems and Reporting in Pharmacy Benefit Management Presentation Developed for the Academy of Managed Care Pharmacy Updated: February.
Chapter 7: Drug Information Resouces. Learning Outcomes Classify drug information request Obtain appropriate background information for drug request Distinguish.
Prepared by: Imon Rahman Lecturer Department of Pharmacy BRAC University.
 Pharmaceutical Care is a patient-centered, outcomes oriented pharmacy practice that requires the pharmacist to work in concert with the patient and.
Documentation in Practice Dept. of Clinical Pharmacy.
Ghada Aboheimed, Msc. Review the principles of an evidence based approach to clinical practice. Appreciate the value of EBM Describe the 5 steps of evidence.
Drug Utilization Review & Drug Utilization Evaluation: An Overview
Introduction to Clinical Pharmacy
Drug Information Resources
Pharmacy practice experience I
AGREEMENT FOR TRANSPARENCY The Case of Mexico
ABSTRACT   Qualitative and Quantitative Assessment of the Essential Medicines List of Delhi State: A Time Series Analysis. Gupta U, Sangeeta S, Baishya.
Pharmacy practice and the healthcare system Ola Ali Nassr
Session 2. Developing and Maintaining a Formulary
APOLLOJAMES LECTURER NANDHA COLLEGE OF PHARMACY
Presentation transcript:

1 Session 2. Developing and Maintaining a Formulary

Objectives  Define the formulary system concept  Understand basic formulary management principles  Describe the benefits of an effective formulary system  Identify criteria used for selection of medicines  Describe basic pharmaceutical information resources for evaluating medicines

Outline (1)  Introduction  Formulary Management Principles  Maintaining a Formulary System  Process for Selecting New Medicines  Selection Criteria for New Medicines  Nonformulary Medicines

Outline (2)  Restricted Pharmaceutical Use  International Nonproprietary Pharmaceutical Names  Information Sources for Evaluating New Medicines  Formulary Manual  Activities  Summary

Key Definitions  Formulary—A list of medicines approved for use in the healthcare system by authorized prescribers  Formulary manual—The document that describes medicines that are available for use in a hospital or clinic (i.e., indications, dosage, length of treatment, interactions, precautions, and contraindications)  Formulary system—A system of periodically evaluating and selecting medicines for the formulary, maintaining the formulary, and providing information in a suitable manual or list

WHO Model Formulary (2004 and 2007)

Benefits of an Effective Formulary System (1)  Approved and efficacious medicines that all practitioners will have available for use  Only the most effective and safest products  Medicines have been evaluated systematically  Medicines are chosen and approved to treat the diseases of the region or country  Physicians develop greater experience with fewer medicines

Benefits of an Effective Formulary System (2)  Pharmaceutical therapy at lower cost  Ineffective, high-cost medicines will be excluded from system  Availability of most effective medicines leads to fewer visits, improved outcomes, and lower cost  Reduced inventory cost

Benefits of an Effective Formulary System (3)  Consistent supply of medicines  Regulating the number of medicines will improve procurement and inventory management  Economies of scale will increase availability of essential medicines  Saving money leads to consistency in purchasing essential medicines which in turn leads to increased availability

Benefits of an Effective Formulary System—Summary  SUPPLY  Easier procurement  Lower amount of stocks  Improved quality assurance  Easier dispensing  PATIENT USE  Focused education efforts  Better compliance  Improved availability  PRESCRIBING  More experience with fewer medicines  Irrational alternatives not available  Focused medicine information  ADRs easier to manage  COST  Lower prices, more competition

Formulary Management Principles (1)  Select medicines on the basis of need (diseases and conditions that have been identified locally)  Select “medicines of choice”  Maintain a limited number of medicines (avoid duplications)  Use INN (generic) names  Use combination (fixed-dose) products only in specific proven conditions (e.g., tuberculosis)

Formulary Management Principles (2)  Use explicit selection criteria that include—  Efficacy and effectiveness  Safety  Quality  Cost  Select medicines that are consistent with national and regional formularies and standard treatment guidelines  Restrict medicines use to appropriate practitioners

Maintaining a Formulary  Evaluate new medicine requests and deletions regularly  Conduct a systematic review of therapeutic groups and classes

Steps to Add or Delete a New Medicine

Steps to Evaluate a Medicine  Compile information resources  Perform evaluation using established criteria  Write medicine monograph describing the evaluation and results  Develop formulary recommendations to present to the DTC  Obtain expert opinion and recommendations  Make a decision at the DTC meeting  Disseminate the results of the evaluation and DTC recommendations

Criteria for Evaluating and Selecting Medicines for Formulary (1)  Disease patterns  Efficacy and effectiveness  Safety  Quality (pharmaceutical products and suppliers)

Criteria for Evaluating and Selecting Medicines for Formulary (2)  Cost and cost-effectiveness of the medicine  Well-known medicines  Health system personnel and expertise available to manage the medicine  Financial resources available to buy the medicine

Nonformulary Medicines  Open formularies  Closed formularies  Management of nonformulary medicines  Limit number of nonformulary medicines  Limit access  Keep a register of all requests for nonformulary medicines (medicine name, quantity, indication)  Review frequently and discuss in DTC meetings

Restricted Medicines (1)  Medicines to be used by specific staff or for specific conditions only  Defined and enforced by the DTC  Necessary to control the use of medicines that should only be used by medical staff with specialized skills  Monitor carefully to ensure the appropriate use

Restricted Medicines (2)  Examples—  Certain antimicrobials for infectious disease specialists  Antipsychotic medicines for mental health professionals  Antineoplastic products for oncologists and internal medicine specialists

International Nonproprietary Names  Trade or brand names  Disadvantages  Nonproprietary or generic names  Advantages in the health care system

Information Resources  Primary Resources  Secondary Resources  Tertiary Resources

Primary Literature—Examples  British Medical Journal  Lancet  New England Journal of Medicine  Journal of the American Medical Association  Annals of Internal Medicine  American Journal of Health-System Pharmacists (AJHP)

Secondary Literature—Examples  Medical letters, newsletters, or bulletins produced by national bodies that monitor medicine efficacy, safety, and cost  Medical Letter (USA), Drug & Therapeutics Bulletin (UK), The International Society of Drug Bulletins  Peer-reviewed journals  Australian Prescriber, Journal Watch, Prescrire  Electronic databases  MEDLINE and EMBASE abstracts  International pharmaceutical abstracts  Cochrane Library abstracts and evaluations

Tertiary Source—Examples  Martindale: The Extra Pharmacopoeia  British National Formulary  USP DI Drug Information  American Hospital Formulary Service (AHFS) Drug Information

British National Formulary

Internet Resources—Examples  MEDLINE  World Health Organization  Centers for Disease Control and Prevention  National Institutes of Health  U.S. Food and Drug Administration  Cochrane Collaboration  Agency for Healthcare Research and Quality

Formulary Manual (1)  Listing of formulary medicines  Alphabetical  Therapeutic category  Medicine information section  Generic name  Dose and strengths  Indications, contraindications, precautions  Side effects  Dosage schedule  Instructions, warnings, interactions

Formulary Manual (2)  Supplementary information for medicines  Price  Regulatory category  Storage guidelines  Patient counseling information  Labeling information  Brand names and synonyms

Formulary Manual (3)  Prescribing and dispensing guidelines  Rational prescribing techniques  Prescription writing principles  Guidelines on quantities to be dispensed  Controlled medicine requirements  ADR reporting requirements  Dispensing guidelines  List of precautionary labels  Medicine interaction tables

Formulary Manual (4)  Treatment protocols  IV medication administration guidelines  Medicines used in pregnancy and lactation  Medicines used in renal failure  Poison guidelines  Prescribing for the elderly

Formulary Manual (5)  Other components  Metric tables  ADR reporting form  Product quality reporting form  Request form for adding or deleting medicines  Request form to use nonformulary medicines  Abbreviations  Indexes

Formulary Manual (6)  Acceptance of a formulary manual requires buy in by—  Opinion leaders  Hospital administration  Senior staff  Professional associations  Manuals must be prepared carefully  Evidenced-based information  Written by experts  Reviewed frequently to be kept up to date

Examples of Rational Drug Selection, Delhi, India*  The essential medicines list (EML) was developed by a multidisciplinary group of experts using criteria of efficacy, safety, and cost  Revised EML saved nearly 30% of money which was used for procuring more medicines resulting in an 80% improved availability in health facilities

Activity 1. Adding a New Antibiotic to the Formulary  Your DTC received an application to add cefapime to the hospital formulary. See Participants’ Guide for more information about this new drug and its use.  What criteria are necessary to evaluate this medicine for addition to the formulary?  Using the principles of formulary management, what major concerns do you have before adding this medicine to the formulary?  What pharmaceutical information resources would be used to analyze this medicine for the DTC? Which sources would be the most useful?

Activity 2. Formulary Management of NSAIDs  Review the list of nonsteroidal anti-inflammatory drugs provided in the Participants’ Guide  Do you think the listed medicines appear logical and well chosen?  How many chemical entities are available on the formulary?  How many NSAID medicines are necessary for a formulary?  What medicines would you recommend to be added or deleted?  What is the best method to list medicines in a formulary? Is this list easy to read and understand?

Summary (1)  Formulary management principles  Select medicines on the basis of need (diseases and conditions that have been identified locally)  Select “medicines of choice”  Avoid duplications and use INN (generic) names  Use combination (fixed-dose) products only in specific proven conditions (e.g., TB)

Summary (2)  Formulary management principles (con’t)  Evaluate and select new medicines according to agreed-upon explicit criteria (including efficacy, safety, quality, cost)  Ensure consistency between the formulary list and the recommended standard treatment guidelines  Regularly review and update the formulary  Monitor and control the use of nonformulary medicines  Restrict medicines to use by appropriate practitioners

Summary (3)  Maintain reliable resources (human, financial, references) for evaluating medicines  Keep the formulary process ethically correct and transparent  Enlist support of key policy makers and influential health professionals to advocate for the DTC and the formulary system